The pink of health: Trade generics now key growth driver for Cipla

Vertical witnesses 25% CAGR in 5 yrs

Mumbai-headquartered Cipla’s trade generics business clocked a compound annual growth rate (CAGR) of 25 per cent over FY18-FY22. Its branded prescription business, on the other hand, clocked a 10 per cent CAGR during the same period.

Trade generics are drugs that are pushed directly to trade and not promoted via doctors.

Cipla’s India business posted a 13 per cent CAGR over the FY18-22 period; the branded generics business accounted for 80 per cent of its  total business in the country.  In FY22, the India business of Cipla clocked 27 per cent year-on-year growth to Rs 980 crore.

According to analysts